UK-based crop biostimulant venture SugaROx has secured a £2.5 million (US$3.3 million) investment from The Mosaic Company as part of its ongoing Series A funding round.

The Mosaic Company invested £400,000 (US$542,000) in SugaROx’s seed round in 2025, supporting the scale-up of its proprietary biostimulant synthesis from laboratory to pilot facility in the UK. This enabled field testing to be extended across five markets.

“We’re delighted to deepen our collaboration with The Mosaic Company as we move closer to commercialisation,” said Mark Robbins, chief executive officer of SugaROx. “Their continued support is a strong validation of both our science and our ability to deliver a differentiated product in a fast-growing market.”

SugaROx’s biostimulant is based on a proprietary form of the natural plant sugar trehalose-6-phosphate (T6P), developed from patented technology from Oxford University and Rothamsted Research.

With this new funding, SugaROx will expand its trial program to validate product performance and generate the data required for regulatory approval and commercial launch in the UK, EU and US.

The venture is targeting a UK product launch in 2027-2028, followed by expansion into the EU and US in 2028-2030. Initial focus crops include wheat and barley in the UK and Europe, and soybean and maize in North America. Work is also underway on horticultural crops.

RELATED
SugaROx secures £1 million to accelerate biostimulant field trials